Tatiana Prowell: Leptomeningeal disease is one of the great unmet needs in oncology
Tatiana Prowell
“Leptomeningeal disease is one of the great unmet needs in oncology. Going to be big when we finally get highly CNS-penetrant drugs or sophisticated CNS drug delivery technology. Predict broad implications for neuro. Who’s up for this device and drug development challenge? Get it.”
Quoting Nancy Lin’s post:
“Comprehensive review this AM on evidence base for IT and systemic tx for leptomeningeal disease (LMD) by Dr Thomas Grinda. Bottom line: we need so much more research and attention to this devastating site of cancer involvement!”
Source: Tatiana Prowell/X and Nancy Lin/X
Tatiana M. Prowell is an Associate Professor of Oncology in the Division of Women’s Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration. She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group. A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic. A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee.